John Hilterman/LinkedIn
Nov 5, 2025, 05:09
Rethinking Anticoagulants in Hospice
John Hilterman, Business Development Manager at Wise Hospice Option, posted on LinkedIn:
”Safer care starts with clearer insight.
For many hospice patients, the goal shifts from prevention to comfort – and that means re-evaluating medications like anticoagulants and antiplatelets.
Our latest Hospice Pharmacist’s Brief outlines when deprescribing is clinically appropriate, how to manage risk, and ways to align therapy with quality-of-life goals.”
Read more here.
Keep up with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM